ESTA

Establishment Labs is finally inflecting operationally. After three flat years ($162M–$166M, FY22–24), revenue jumped 27.1% to $211M in FY2025, driven by the September 2024 FDA approval of Motiva Implants unlocking North America, plus EMEA (+16.4%) and Latin America (+14.1%) — partially masked by a 28.6% APAC drop the company attributes to distributor purchase timing. Quality improved alongside volume: gross margin expanded to 69.3% from 66.0% on higher US selling prices, and the net loss nearly halved to -$51.1M from -$84.6M, with operating loss narrowing to -$39.0M. This is a credible, FDA-catalyzed growth story with a premium-priced, differentiated product.

The problem is the balance sheet and the price. Stockholders' equity has been hollowed out to just $23.5M (down 55.7%) against $334M of liabilities — a 14.2x liabilities/equity ratio and a -$496M accumulated deficit. Long-term debt sits at $248M, and the MD&A's cash-requirements table shows $246.4M of principal coming due in 2027 — a refinancing wall against only $75.6M of cash that is shrinking (-16.4%) while the business still burns ~$50.9M in operating cash flow annually. Interest expense climbed to $25.3M and is rising with principal. FY2025 financing leaned on a $24.5M Tranche D term loan and $10M of short-term notes — incremental, not transformational, funding. Note too that part of the SG&A increase and the tax benefit are low-quality: a $4.4M contingent-consideration remeasurement, +$1.5M bad-debt expense, and a one-off valuation-allowance release drove the $7.0M tax benefit.